FMP

FMP

Enter

CDXC - ChromaDex Corpo...

photo-url-https://images.financialmodelingprep.com/symbol/CDXC.png

ChromaDex Corporation

CDXC

NASDAQ

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

5.61 USD

0.17 (3.03%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Mr. Robert N. Fried

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingred...

CIK

0001386570

ISIN

US1710774076

CUSIP

171077407

Address

10900 Wilshire Boulevard

Phone

310 388 6706

Country

US

Employee

106

IPO Date

Jun 25, 2008

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

CDXC Financial Summary

CIK

0001386570

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

171077407

ISIN

US1710774076

Country

US

Price

5.61

Beta

1.88

Volume Avg.

1.3M

Market Cap

428.51M

Shares

-

52-Week

1.36-7.97

DCF

-3.65

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

280.5

P/B

-

Website

https://www.chromadex.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest CDXC News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep